Literature DB >> 6185615

Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity.

J L Urban, H Schreiber.   

Abstract

The ultraviolet radiation-induced fibrosarcoma 1591 is generally rejected by normal syngeneic mice, but occasionally the tumor succeeds in growing progressively. Analysis of these progressively growing tumors has regularly demonstrated the development of tumor variants that have acquired a heritable progressive growth potential. We have analyzed the phenotypic changes of these variants to determine which kind of selection pressure had occurred during the evolution of the variants, thus giving insight into the relative importance and hierarchy of the different immune defense mechanisms that may be operating in normal individuals as a defense against neoplastic cells. We discovered that all of the host-selected progressor variants had lost not only a strong T cell-recognized and tumor-specific antigen, but also their high sensitivity to cytotoxic macrophages. No selection for macrophage-resistance or loss of the tumor antigen was observed in 1591 tumors reisolated from idiotypically-suppressed mice or from other mice lacking tumor-specific T cell immunity. Analysis of other tumor variants selected in vitro showed that 1591 tumor cells have the potential to lose sensitivity to tumoricidal macrophages without losing the T cell-recognized tumor antigen. Thus the data suggest that T cells and macrophages act together to suppress the outgrowth of potentially malignant cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6185615      PMCID: PMC2186944          DOI: 10.1084/jem.157.2.642

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  A functional comparison of tumor cell killing by activated macrophages and natural killer cells.

Authors:  J C Roder; M L Lohmann-Matthes; W Domzig; R Kiessling; O Haller
Journal:  Eur J Immunol       Date:  1979-04       Impact factor: 5.532

2.  Detection of either rapidly cytolytic macrophages or NK cells in "activated" peritoneal exudates depends on the method of analysis and the target cell type.

Authors:  J D Gray; C G Brooks; R W Baldwin
Journal:  Immunology       Date:  1981-04       Impact factor: 7.397

3.  Evidence for a multistep mechanism of cytolysis by BCG-activated macrophages: the interrelationship between the capacity for cytolysis, target binding, and secretion of cytolytic factor.

Authors:  D O Adams; P A Marino
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

4.  Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide.

Authors:  J L Pace; S W Russell
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

5.  Studies on natural killer (NK) cells. I. NK cell specific antibodies in CE anti-CBA serum.

Authors:  R C Burton; H J Winn
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

6.  Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation.

Authors:  M S Meltzer
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

7.  Macrophage content of metastatic and nonmetastatic rodent neoplasms.

Authors:  J E Talmadge; M Key; I J Fidler
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

8.  Macrophage-induced enhancement of endogenous tumor lysosome activity.

Authors:  J L Urban
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

9.  Alloreactive cloned T cell lines. I. Interactions between cloned amplifier and cytolytic T cell lines.

Authors:  A L Glasebrook; F W Fitch
Journal:  J Exp Med       Date:  1980-04-01       Impact factor: 14.307

10.  Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis.

Authors:  C F Nathan; B A Arrick; H W Murray; N M DeSantis; Z A Cohn
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

View more
  16 in total

1.  Characterization of gene expression profiles of T cells during anti-tumor response.

Authors:  Christian Stremmel; Renate Siebenhaar; Roland Croner; Bertram Reingruber; Anthony J Slavin; Werner Hohenberger
Journal:  Int J Colorectal Dis       Date:  2005-04-06       Impact factor: 2.571

Review 2.  Resistance of tumor cells to tumor necrosis factor.

Authors:  H M Shepard; G D Lewis
Journal:  J Clin Immunol       Date:  1988-09       Impact factor: 8.317

3.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

Review 4.  Macrophage infiltration and tumor progression.

Authors:  S J Normann
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

5.  The effect of adherence on the in vitro induction of cytocidal activity by macrophages.

Authors:  A Friedman; D I Beller
Journal:  Immunology       Date:  1987-08       Impact factor: 7.397

6.  Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule.

Authors:  C Philipps; M McMillan; P M Flood; D B Murphy; J Forman; D Lancki; J E Womack; R S Goodenow; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

7.  Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines.

Authors:  R D Wortzel; J L Urban; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

8.  Effects of in vivo 'priming' on endotoxin-induced hypotension and tissue injury. The role of PAF and tumor necrosis factor.

Authors:  X M Sun; W Hsueh; G Torre-Amione
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

9.  Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.

Authors:  D L Hines
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

Authors:  J L Urban; H M Shepard; J L Rothstein; B J Sugarman; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.